secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2021-12-14T23:59:59+00:00
Accession:  0000899923-21-000097
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics promotes Nicole Lambert to COO effective Jan 1, 2022
--------------------------------------------------------------------

- Appointed COO effective Jan 1, 2022; previously Group President over Oncology, Women's Health, International.
- Received one-time award of 10,000 time-based RSUs vesting over 4 years; base salary increased to $499,963.
- Lambert has 20-year tenure at Myriad; also serves on board of Arcus Biosciences (NYSE: RCUS).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992321000097/0000899923-21-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992321000097/mygn-20211214.htm
  HTML page:      https://secwatch.observer/filing/0000899923-21-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer